NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.
4SC AG and Merck KgaA have signed a supply agreement to start clinical tests of Merck’s checkpoint blocker avelumab plus 4SC’s HDAC I blocker domatinostat.
Mutabilis and IBT Vaccines have successfully bagged US$12m from the Novo Holdings REPAIR Impact Fund.
Critical care experts have presented data supporting the thesis that three specific pathways are the cause for about 90% of sepsis mortality.
Antabio SAS has got a US-$4.4m tranche from CARB-X to advance preclinical development of its P. aeruginosa treatment in Cystic Fibrosis patients
Swedish and Danish researchers have created a hydrogel that kills various types of bacteria and reduces inflammation in mice and pigs with infected wounds.
The technology of Oxford-based Oxford Biodynamics (OBD) promises insights into why immunotherapies only work in some patients but not in all. A major US pharma company now wants to validate OBD’s epigenetic biomarker discovery and development platform causing a share price gain of 15%.
Paris-based European venture capital company Truffle Capital closed its €250m BioMedTech fund – celebrating its company building approach.
Basel-based biopharma company Cellestia Biotech AG has successfully closed a Series B financing round, raising a total of CHF 20 million.
Data from 1,200 heart failure patients demonstrate that high discharge levels of the biomarker bio-ADM® (bioactive Adrenomedullin) indicate residual congestion in heart failure patients.